ENTITY
Astellas Pharma

Astellas Pharma (4503 JP)

133
Analysis
Health CareJapan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
bullishLY
03 Oct 2019 19:30

The BIG BUY of Z

18 months ago, Altaba Inc (AABA US) announced it would start selling down its 2bn shares-plus of Yahoo Japan - as of two days ago renamed Z...

Logo
771 Views
Share
20 Dec 2018 05:24

Japan: The 2018-Q3 Cash Flow Stakes - Runners, Riders & Red Flags

JAPAN CORPORATE CASH FLOW UPDATE - This insight updates our previous Insight Yen Weakens > Normal Service Resumed with data from all of the...

Logo
697 Views
Share
18 Dec 2018 14:43

Japan Pharma - Top Picks

While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP)  is a contrarian call in anticipation of value...

26 Nov 2018 09:09

Is It a Nikkei BOJ Squeeze on Nikkei 225 Low Float Names? Or Just FamilyMart Being FamilyMart?

A comment from a Smartkarma client prompted me to dig through this. It was an interesting comment suggesting the high weight Nikkei 225 names,...

Logo
600 Views
Share
bullishAstellas Pharma
31 Oct 2018 22:56

Astellas 1H FY18 (YE Mar'19) Results - First Glance

Key highlights Key drivers including, Xtandi (up 17% to ¥164b) and Mirabegron (up 19% to ¥69b) drove overall sales up by 1% to ¥647b Favorable...

x